Polycaprolactone (PCL) micro- and nanoparticles produced using the electrospraying technique present high drug encapsulation capacity, a controllable surface area, and a good cost–benefit ratio. PCL is also considered a non-toxic polymeric material with excellent biocompatibility and biodegradability. All these characteristics make PCL micro- and nanoparticles a promising material for tissue engineering regeneration, drug delivery, and surface modification in dentistry. In this study, PCL electrosprayed specimens were produced and analyzed to determine their morphology and size. Three PCL concentrations (2, 4, and 6 wt%) and three solvent types (chloroform (CF), dimethylformamide (DMF), and acetic acid (AA)) with various solvent mixtures ratios (1:1 CF/DMF, 3:1 CF/DMF, 100% CF, 1:1 AA/CF, 3:1 AA/CF, and 100% AA) were used while keeping the remaining electrospray parameters constant. SEM images followed by ImageJ analysis showed a change in the morphology and size of the particles among various tested groups. A two-way ANOVA demonstrated a statistically significant interaction (p < 0.001) between PCL concentration and solvents on the size of the particles. With the increase in the PCL concentration, an increase in the number of fibers was observed among all the groups. The morphology and dimensions of the electrosprayed particles, as well as the presence of fibers, were significantly dependent on the PCL concentration, choice of solvent, and solvent ratio.

The design and development of multifunctional nanoparticles have attracted great interest in biomedical research. This study aims to prepare pH-responsive melanin-like nanoparticles for T₁-weighted magnetic resonance imaging (MRI) and photothermal therapy. The new multifunctional nanoparticles (amino-Fe-PDANPs) are synthesized by copolymerization of dopamine and its derivative amino-N-[2-(diethylamino) ethyl]-3,4-dihydroxy-benzenepropanamide (N-Dopa) at room temperature. The size of nanoparticles can be controlled by NaOH concentration. The incorporation of N-Dopa is characterized by NMR and FT-IR. From transmission electron microscopy (TEM), the nanoparticles exhibit excellent dispersion stability in water and are spherical in shape. The MRI measurement has demonstrated that amino-Fe-PDANPs have a significant signal enhancement in responding to the acidic solution. Confirmed by the photothermal study, the nanoparticles exhibit a high photothermal conversion efficiency. The melanin-like multifunctional nanoparticles integrate both diagnosis and therapeutic functionalities, indicating the potential for theranostic application.

Melanoma is an aggressive form of skin cancer with a very high mortality rate. Early diagnosis of the disease, the utilization of more potent pharmacological agents, and more effective drug delivery systems are essential to achieve an optimal treatment plan. The applications of nanotechnology to improve therapeutic efficacy and early diagnosis for melanoma treatment have received great interest among researchers and clinicians. In this review, we summarize the recent progress of utilizing various nanomaterials for theranostics of melanoma. The key importance of using nanomaterials for theranostics of melanoma is to improve efficacy and reduce side effects, ensuring safe implementation in clinical use. As opposed to conventional in vitro diagnostic methods, in vivo medical imaging technologies have the advantages of being a type of non-invasive, real-time monitoring. Several common nanoparticles, including ultrasmall superparamagnetic iron oxide nanoparticles, silica nanoparticles, and carbon-based nanoparticles, have been applied to deliver chemotherapeutic agents for the theranostics of melanoma. The application of nanomaterials for theranostics in molecular imaging (MRI, PET, US, OI, etc.) plays an important role in targeting drug delivery of melanoma, by monitoring the distribution site of the molecular imaging probe and the therapeutic drug in the body in real-time. Hence, it is worthwhile to anticipate the approval of these nanomaterials for theranostics in molecular imaging by the US Food and Drug Administration in clinical trials.